IMBiologics

IMBiologics is a biotechnology company founded in August 2020. Our goal is to invent new treatments for autoimmune diseases and cancer, using antibodies to modulate the immune system through innovative mechanisms of action. In 2020, we launched a KRW 4 billion seed fund to develop proprietary antibody platform technology and internally research and develop novel licensed antibody assets.